Compare GSK plc (GSK) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PulteGroup, Inc. — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while PulteGroup, Inc. trades at $127.65 (market cap $23.89B). The key difference: GSK plc is far larger — about 4.2× PulteGroup, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | PHM | |
|---|---|---|
Market Cap | $101.34B | $23.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $142.56 |
52-Week Low | $36.20 | $108.65 |
Enterprise Value | $121.95B | $23.84B |
Dividend Yield | 3.49% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
PulteGroup (PHM) trades at $127.11, up 2.05% today, with a bullish technical signal and strong profitability metrics including a 12.14% net margin. Recent earnings show mixed results with a Q3 2025 beat but subsequent misses, while cash flow trends improved in 2025. The stock is near its 52-week high of $144.50, reflecting resilience despite housing market headwinds from rising mortgage rates.
Outlook is cautiously optimistic with a consensus price target of $145.20 offering 14% upside, but risks include margin pressure from discounts and rate buydowns. Investment opportunity hinges on execution amid affordability challenges, with analyst sentiment balanced between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
